For the Inventor, By the Inventor

Enter assignee name

Tel Aviv, Israel

Redhill Biopharma Ltd.

USPTO Granted Patents = 43

% Expired Patents = 2.3

EPO Patents = 8

Trademarks = 7

Forward Citations = 65

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Reza Fathi (34 out of 43 patents)

Dror Ben-Asher (17 out of 17 patents)

Patrick Gosselin (16 out of 20 patents)

4. Guy Goldberg (14 out of 14 patents)

5. Gilead Raday (11 out of 11 patents)

6. Thomas Julius Borody (9 out of 111 patents)

7. Danielle Abramson (4 out of 4 patents)

8. Patrick Laughlin Mclean (2 out of 2 patents)

9. Ofra Barnett (2 out of 2 patents)

10. Kely Lee Sheldon (2 out of 2 patents)

11. Patrick Laughlin McLean (1 out of 2 patents)

12. Mark L Levitt (1 out of 2 patents)

13. Patricia Anderson (1 out of 1 patent)

14. Elliot Offman (1 out of 1 patent)

15. Harry Jefferson Leighton (1 out of 11 patents)

Core Competencies:

Sphingosine Kinase 2 Inhibitor

Coronavirus Infection

Helicobacter Pylori

Cancer Treatment

Combination Therapy

Serine Protease Inhibitor

Ebola Treatment

Triple Antibiotic

Inflammatory Bowel Disease

Colonic Evacuation

Pulmonary Infections

Autoimmune Disease

43 patents: Sort by Forward Citations

1. 12569475 - Method for eradicating helicobacter pylori infection in patients regardless of body mass index (2026-03-10),

2. 12551469 - Sphingosine kinase 2 inhibitor for treating coronavirus infection (2026-02-17),

3. 12502381 - Serine protease inhibitor for treating coronavirus infection (2025-12-23),

4. 12370206 - Therapy for inhibition of single-stranded RNA virus replication (2025-07-29),

5. 12115150 - Biomarkers of coronavirus pneumonia (2024-10-15),

6. 11931463 - All-in-one fixed-dose combination for treatinginfection (2024-03-19),

7. 11918560 - Serine protease inhibitor for treating coronavirus infection (2024-03-05),

8. 11878011 - Method for eradicatinginfection in patients regardless of body mass index (2024-01-23),

9. 11786541 - Inhibitor of sphingosine kinase 2 for treating Ebola (2023-10-17),

10. 11633385 - Combination compositions for treatment of cancer (2023-04-25),

11. 11590154 - Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections (2023-02-28),

12. 11471448 - Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia (2022-10-18),

13. 11364227 - Sphingosine kinase 2 inhibitor for treating coronavirus infection (2022-06-21),

14. 11135172 - Rifabutin-based compositions and methods for treatinginfection (2021-10-05),

15. 11090326 - Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine (2021-08-17),

Company Overview

Redhill Biopharma Ltd. is a biopharmaceutical company based in Tel Aviv, Israel, focused on developing innovative therapies for gastrointestinal diseases and infectious diseases. The company specializes in advanced treatments targeting single-stranded RNA viruses, including coronaviruses, and employs mechanisms such as sphingosine kinase 2 inhibition and serine protease inhibition. Redhill's portfolio includes fixed-dose combinations and therapies for conditions like cancer, Ebola virus, and Helicobacter pylori infections, reflecting its commitment to addressing critical health challenges.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

43 Patents

#19 in Tel Aviv

#126 in Israel

#16,040 in the World

Tel Aviv, Israel

Redhill Biopharma Ltd.

Forward Citations = 65

19 inventors:

Reza Fathi (34 out of 43 patents)

Dror Ben-Asher (17 out of 17 patents)

Patrick Gosselin (16 out of 20 patents)

4. Guy Goldberg (14 out of 14 patents)

5. Gilead Raday (11 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Redhill Biopharma Ltd.. Retrieved from https://idiyas.com/company/redhill-biopharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…